RNS Number : 9552Z
  Celsis International PLC
  25 July 2008
   

    Stock Exchange announcement
    FOR release: Friday 25 July 2008

    CELSIS INTERNATIONAL PLC
    ("Celsis", "the Company" or "the Group")

    Share options and treasury shares

    25 July 2008: Celsis International plc, the international life sciences products and laboratory services company, today announces that
according to the 2005 Share Performance Plan, Jay LeCoque, Chief Executive and Christian Madrolle, Finance Director, have respectively been
awarded 146,858 and 141,883 Share Options at a price of 5 pence per share on 23 July 2008.

    These Share Options are subject to the achievement of performance criteria as detailed in the Share Performance Plan.

    Celsis International plc also announces that on 24 July 2008 the Company purchased 184,015 of its Ordinary Shares of 5 pence, at a block
trading price of 136.85 pence per share, to be held as Treasury Shares. 

    Following the purchase, the Company has 570,515 Treasury Shares. Excluding Treasury Shares, the Company has 21,912,528 Ordinary Shares
of 5 pence each in issue. 

 Enquiries:

 Celsis International plc                            Tel: +44 (0) 1223 598 428
 Christian Madrolle, Finance Director and
 Company Secretary
 Jenny Woolway, Corporate Communications

 Financial Dynamics                                  Tel: +44 (0) 20 7831 3113
 David Yates
 Jonathan Birt

    Notes to editors
    Celsis International plc  
    Celsis International plc is a leading international provider of innovative life science products and laboratory services to the
pharmaceutical and consumer products industries. Each Celsis division has the capacity to deliver substantial time and cost savings to its
customers, in addition to ensuring product quality and safety for consumers. Celsis' extensive client base includes many of the world's
leading pharmaceutical and consumer products companies. The Company is listed on the London Stock Exchange (CEL.L).

    Celsis Rapid Detection division utilises proprietary enzyme technology to develop and supply diagnostic testing instruments and
consumables for the rapid detection of microbial contamination in pharmaceutical and consumer products. These rapid testing systems provide
significant economic value by reducing the time it takes to test and release raw materials, in process and finished goods to market. 

    Celsis Analytical Services division provides cost effective outsourced laboratory testing services to pharmaceutical companies. Its
comprehensive service offerings include a full spectrum of laboratory services from drug development and discovery to analytical chemistry
and biological sciences to stability storage and testing. 

    Celsis In Vitro Technologies (Celsis IVT) employs proprietary expertise in hepatocyte (liver cell) technology to supply in vitro testing
products to the pharmaceutical industry. Celsis IVT's consumable testing products screen drug compounds for liver toxicity early in the drug
discovery process, thereby reducing the time and cost of further development or trial on those compounds which will not be properly
metabolised by the human liver. 

    Further information can be found on its website at www.celsis.com.

This information is provided by RNS
The company news service from the London Stock Exchange
 
  END 
 
MSCUVUNRWWRBUAR
Celadon Pharmaceuticals (LSE:CEL)
Historical Stock Chart
From Jun 2024 to Jul 2024 Click Here for more Celadon Pharmaceuticals Charts.
Celadon Pharmaceuticals (LSE:CEL)
Historical Stock Chart
From Jul 2023 to Jul 2024 Click Here for more Celadon Pharmaceuticals Charts.